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THE BURDEN OF CERVICAL CANCER 
 In 400 B.C Hippocrates described cervical cancer as incurable. We have come 
a long way since then and the rate of cure of cervical cancer is on the rise while the 
incidence and death due to cervical cancer is on the decline.  
 It is the 4th most common cancer in females in the world [1] and the second 
most common cancer in females in India only after breast cancer [2]. The incidence 
of cervical cancer is on the decline not only in the urban population but also in the 
rural population. The reason for this decline is likely to be due to late marriage, 
family planning, improvement in education and socio-economic status. The 
awareness of the disease, genital hygiene and the availability of doctors may also 
contribute to the decline in the incidence [3]. Although many cervical cancers are 
picked up in the early stages due to active screening and awareness, the majority of 
cervical cancer patients present in the locally advanced stage especially in the 
developing countries. 
 In the modern era, with the advances in the management of cervical cancer, the 
outcome of early cervical cancer has dramatically improved but the more locally 
advancer cervical cancers are still a cause for concern. 
 In developing countries, about 40-45 % cervical cancer patients present in the 
more locally advanced stage. While concurrent chemoradiation followed by 
brachytherapy is the treatment of choice for locally advanced cervical cancers, there 
are several factors that complement treatment and improve the local control. 
 The pattern of failure in locally advanced cervical cancers is mainly due to 
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poor local control while only a small number of patients develop distant metastasis. 
This has led to the need to explore treatment strategies to improve the local control. 
Several treatment strategies have been evolving in the last few decades from the 
introduction of chemotherapy and other radiosensitizers to the advancement in 
brachytherapy, delivery of external beam radiation therapy, introducing hyperthermia 
and improving patient related factors. Before we investigate the strategies to improve 
the management of locally advanced cervical cancers, it is essential to understand the 
magnitude of the disease. 
  
 EPIDEMIOLOGY 
 Cervical cancer is the 4th most common cancer in females worldwide with an 
annual incidence of 510,000 cases and approximately 288,000 deaths per year. In 
south asia, India has the highest age standardized incidence of cervical cancer at 22 
[4]. In India, cervical cancer is the 2nd most common cancer in females with an 
annual incidence of 122,844 cases and approximately 288,000 deaths per year. 
 The recent national cancer registry programme (NCRP) data between 2009 and 
2011 showed that the highest incidence at an age adjusted rate was in Aizwal district 
in the north eastern part of India, followed by Bashi and Bangalore [5]. 
 In Chennai the age adjusted risk has reduced from 41 to 16.7 in 2009 [6]. As 
per the madras metropolitan tumour registry (MMTR), the majority of the cases 
present in Stage II and Stage III with a DFS and OS of 67.1 % and 62.3% 
respectively across all stages. 
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TREND OF CRUDE INCIDENCE RATE AND AGE STANDARDIZED RATE  
MMTR – MADRAS METROPOLITAN TUMOUR REGISTRY 
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CRUDE INCIDENCE RATE AND AGE STANDARDIZED RATE 
 
Regions No. of Cases CIR ASR 
World 527624 15.1 14.0 
More Developed Region 83078 13.0 9.9 
Less Developed Region 444546 15.6 15.7 
India 122844 20.2 22.0 
Chennai(2012-13) 783 16.7 15.9 
 
Number of cases at Cancer Institute over the years  
                     Year                       Cases 
 
2006 562 
2007 545 
2008 385 
2009 368 
2010 455 
2011 474 
2012 470 
2013 526 
2014 505 
2015 452 
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 The word cervix is derived from latin which means neck and it has been 
described anatomically from the time of Hippocrates. The understanding of the 
anatomy of the cervix, its relation to the pelvic organs, the draining lymph node, its 
development and staging are fundamental prior to the decision on management. 
DEVELOPMENT OF CERVIX 
 The uterus, fallopian tube, cervix and the upper vagina arise from the 
paramesonephric or mullerian duct. As it is known, there are three germ layers the 
ectoderm, endoderm and mesoderm. The intraembryonic mesoderm is subdivided 
into the para-axial mesoderm, the lateral plate mesoderm and the intermediate 
mesoderm. The intermediate mesoderm connects the para-axial mesoderm with the 
lateral plate and differentiates into the urogenital structures [7]. The intermediate 
mesoderm forms a bulging on the posterior abdominal wall called nephrogenic cord. 
This gives rise to the Gonads, mesonephros, mesonephric duct and paramesonephric 
duct [8]. The paramesonephric duct is formed by the invagination of the coelomic 
epithelium and as the name suggests, it lies lateral to the mesonephric duct. The two 
paramesonephric ducts cross the mesonephric ducts cross the mesonephric duct and 
fuse at the midline to form the uterovaginal canal. This is called mullerian 
organogenesis. The cranial end of the fused ducts will eventually form the uterus and 
the cervix, the unfused cranial ends will form the fimbrial portion of the fallopian 
tubes and the caudal end of the fused ducts will form the upper 2/3rd of vagina. In the 
fetus the cervical part is larger than the body of the uterus [9]. 
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ANATOMY 
 The uterus is a hollow, muscular organ in the pelvic cavity composing the 
fundus, body, isthmus and cervix. It is situated between the bladder anteriorly and the 
rectum posteriorly. The normal position of the uterus is Anteverted and anteflexed. 
The angle formed by the long axis of the uterus and the long axis of the vagina by the 
forward bending of the uterus over the vagina of about 90 degrees is called 
Anteversion.The angle that the uterus flexes on itself is about 120 degrees and is 
called anteflexion. 
 The uterus communicates superiorly on either side with the fallopian tube and 
inferiorly with the vagina through the cervix. 
 The cervix is the lower fibromuscular portion of the uterus supported by the 
cardinal ligament or ligament of Mackenrodt laterally and the uterosacral ligaments 
posteriorly. The shape and size of the cervix vary depending on the woman's age, 
parity and hormonal status. While the external os is round in  nulliparous women, it is 
slit like in parous ladies.   
 The cervix is anatomically divided into the supravaginal part and the vaginal 
part. The vaginal part is also called portio vaginalis which protrudes into the vagina 
and opens through the external os. The isthmic portion of the uterus meets the cervix 
at the internal os. Ectocervix is the part of cervix lying exterior to the external os and 
the endocervix lies proximal to it. The canal between the internal and external os is 
called Endocervical canal. The part of vagina adjacent to the portio vaginalis is the 
fornix. The anterior fornix is close to the vesico uterine pouch while the posterior 
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fornix is deeper and is close to the rectouterine pouch. 
 The cervical stroma is composed of dense, fibro-muscular tissue through which 
vascular, lymphatic and nerve supplies to the cervix pass and form a complex plexus. 
The arterial supply of the cervix is by the cervical and vaginal branches of the uterine 
artery which is a branch of the internal iliac artery. The veins run parallel to the 
arteries and drain into the hypogastric plexus. 
 The lymphatic drainage of cervix is through three main lymphatic channels. 
The lateral channel drains into the paracervical lymphnodes and then to the external 
iliac (of which obturator is the innermost) and hypogastric nodes.The anterior 
lymphatic channels pass behind the bladder and terminate in external iliac nodes. The 
posterior channels course through the uterosacrals and terminate in common iliac, 
subaortic, para-aortic and superior rectal nodes. The pelvic lymphatics drain into the 
common iliac and para-aortic lymph nodes [11].  
 The three main para-aortic chains are the Left aortic chain, the aortocaval and 
the caval chain. Lymph is then transported cranially to the cisterna chyli , the thoracic 
duct and eventually the Left supraclavicular node [10] 
 The nerve supply to the cervix is from the hypogastric plexus. Sensory nerve 
endings are very few in ectocervix and extensive in endocervix. Hence ectocervix 
punch biopsy is tolerated in most women even without local anesthesia. Since 
sympathetic and parasympethetic fibres are abundant in endocervix, dilatation and 
curettage may lead to vasovagal reaction. 
  
  
 
 
 
 
ANATOMY OF CERVIX IN RELATION TO OTHER 
LYMPHATIC DRAINAGE OF CERVIX
8 
 
PELVIC ORGANS 
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Probability of Lymph nodal metastasis 
Stage Pelvic nodal 
metastasis % 
Para-aortic nodal 
metastasis % 
I.A.1 <1  
I.A.2 <5  
I.B 10 5-8 
II.A 15 10 
II.B 20 15 
III.A 25-30 20 
III.B 40-50 30-35 
IV 50-60 40-45 
 
 
 The normal epithelium of the ectocervix is the Stratified, non keratinizing 
squamous epithelium. It is made of 15 to 20 layers of cells. This squamous epithelium 
is made up of the basal layer, the para basal layer, the intermediate and the superficial 
layer. The epithelium is separated from the underlying stroma by the basement 
membrane which is usually straight but occasionally has stromal projections called 
papillae. The epithelium between the papillae are called rete pegs.  The basal layer is 
a single layer of round cells found just above the basement membrane with a large 
dark staining nuclei and scanty cytoplasm. The basal cells mature and divide to form 
the next few layers of cells called the para basal cells which also contain large dark 
staining nuclei with greenish blue basophilic cytoplasm. This layer of cells further 
mature and divide to form layers of polygonal cells called intermediate layer with 
abundant cytoplasm and small round nuclei. These cells mature further to form the 
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superficial layer composed of large, flattened cells with small dense nuclei and 
transparent cytoplasm.  The superficial and intermediate layer of cells contain 
abundant glycogen in their cytoplasm which is a normal sign of maturation called 
glycogenation. The maturation of the squamous epithelium of cervix is estrogen 
dependent hence, in postmenopausal women the epithelial cells do not mature beyond 
the parabasal layer. The endocervix is lined by a single layer of columnar epithelium 
comprising tall cells with dark staining nuclei lying close to the basement membrane. 
 The junction between the columnar epithelium and the squamous epithelium is 
called the Squamocolumnar junction (SCJ). With age and puberty, the 
Squamocolumnar junction everts to expose portions of the columnar epithelium onto 
the ectocervix. This is referred to as Ectropion. Due to the irritation of the acidic 
vaginal environment, the ectropion undergoes squamous metaplasia. The area 
between the original squamocolumnar junction and the new squamocolumnar 
junction is called the Transformation zone. 
 
HPV IN LOCALLY ADVANCED CERVICAL CANCER 
      Harald Zur Hausen , a German virologist, first isolated HPV 6 DNA from genital 
wart by simple centrifugation as early as 1977. This lead to further research and 
identification of HPV 16 in 1983 and later HPV 18 by southern blot hybridization 
[91]. He received the Nobel Prize in physiology or medicine in 2008. 
 
 
STRUCTURE OF HPV: 
 
 
      The human papilloma viruses are small,
viruses that have a diameter of 50
double-stranded DNA molecule of about 8000 base
composed of 72 pentameric capsomer proteins. The capsid contains two structural 
proteins –the late L1 and L2 
in the replication cycle. The genomes of all HPV types contain approximately eight 
open reading frames (ORFs) that are transcribed from only one DNA strand. The 
ORF’s are classified into three functional parts: 
1.The early (E) region that encodes proteins (E1
2.The late (L) region encoding the structural proteins (L1
assembly, and  
3.A largely non-coding part that is referred to as the long control region (LCR) 
which contains cis elements nece
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  non-enveloped,  icosahedral DNA 
–55 nm. The viral particles contain a single 
-pairs contained in a capsid 
— which are both virally encoded and e
 
–E7) -For viral  replication, 
–L2)-For virion 
ssary for viral replication and transcription [
 
 
 
 
 
xpressed late  
 
 
 
 
 
92] . 
TYPES OF HPV: 
There are more than 100 types of HPV, of which at least 13 are oncovirus 
(high risk type). >90% of cervical cancers are HPV associated and are contracted 
through sexual intercourse [93
cancers and precancerous cervical lesions
 
RISK GROUPS: 
Risk according to clinical sequelae 
High Risk  16, 18
Probable High risk  26, 53, 66
Low risk  6,11, 40, 42, 43, 44, 54, 61, 70, 72, 81, CP6108
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].Two HPV types (16 and 18) cause 70% of cervical 
 [94] . 
  
, 31,33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 & 82
  
 
 
 
 
  
  
PATHOGENESIS: 
 
 
RISK FACTORS FOR HPV INFECTION:
1)  Early first sexual intercourse 
2)  Multiple sexual partners  
3)  Tobacco use–Smoking 
4)  Immune suppression-Co existing HIV infection.
5)  Male partner sexual behavior
6)  Large number of pregnancies
7)  History of sexually transmitted diseases
1
• Virus spread by contact
• Through sexual intercourse
2
• Microabrasions of epithelial surface but the basal lamina intact
3
• Interaction between 
4    
• Entry of HPV into the basal layer of stratified epithelia by 
endocytosis
5
• HPV genome integrates into host chromosome and codes for the 
early and late proteins
6
• E6 inactivates p53 gene causing chromosomal instability,inhibits 
apoptosis and activates telomerase
7
• E7 protein affects the retinoblastoma gene resulting in loss of 
regulation of cells proliferation and immortalization.
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-Gonorrhea, Chlamydia or 
virions and basal keratinocytes
 
herpes simplex. 
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NATURAL HISTORY: 
HPV prevalence peaks at ages 25 to 35(6).In  less than 15% of exposed 
women, persistent infection develops resulting in dysplasia. Majority, clear the 
infection within a period of 2 years [93]. Cervical cancer develops 10 to 20 years 
after the exposure to HPV. Women in whom coexisting immunodeficiency and whose  
spouses have higher exposure to HPV have higher incidence of persisting infection  
which later transforms to cervical carcinoma. 
 Lindel K et al investigated the significance of HPV positivity in 40 patients 
with advanced cervical cancer treated with radiation therapy. The results of  this study 
revealed that HPV positivity had better disease free survival (p=0.02), overall 
survival (p<0.02) and progression free survival (p,0.05) which was significant. 
Clinical complete remission was seen more in HPV positive tumours (67% vs 33%). 
A better disease free survival trend was seen with intact E2 gene region. 
 In a retrospective study of 223 cases of cervical cancer it was found that HPV 
16 was found to have an impact on overall survival independently (p<0.002). 
 In 106 patients treated with radical radiotherapy, reduced survival and poor 
response was seen in the presence of multiple HPV types. 
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FIGO STAGING OF CERVICAL CANCER 
STAGE I Tumour confined to the uterus 
 
I.A Microscopic disease 
 
I.A.1 Stromal invasion less than 3 mm in depth and less than 7mm 
horizontal spread 
I.A.2 Stromal invasion between 3 to 5 mm in depth and less than 7mm 
horizontal spread 
I.B Clinically visible lesion or microscopic lesion greater than I.A 
 
I.B.1 Clinically visible < 4 cm 
 
I.B.2 Clinically visible > 4 cm 
 
STAGE II Tumour extends beyond the uterus but not upto lateral pelvic 
wall or lower third of vagina 
II.A Tumour without parametrial extention 
 
II.A.1  < 4 cm in greatest dimension 
 
II.A.2 > 4 cm in greatest dimension 
 
II.B Tumour with parametrial extension 
STAGE III Tumour extends to the pelvic side wall / involves lower third of 
vagina / Hydroureteronephrosis or non functioning kidney 
III.A Extension into the lower third of vagina 
 
III.B Tumour extends to the pelvic side wall or causes 
Hydroureteronephrosis or non functioning kidney 
STAGE IV Spread to pelvic organs or distant metastasis 
 
IV.A Tumour involves the mucosa of bladder or rectum or extension 
beyond the true pelvis 
IV.B Distant metastasis 
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EVALUATION RECOMMENDED BY FIGO 
 INSPECTION 
 PALPATION 
 ENDOCERVICAL CURETTAGE 
 HYSTEROSCOPY 
 CYSTOSCOPY 
 PROCTOSCOPY 
 IV UROGRAPHY 
 X-RAY CHEST AND SKELETAL X-RAYS. 
 
 
DRAWBACKS OF FIGO STAGING 
 Clinical staging with minimal investigations.  
 Optional imaging with MRI/CT/USG/PET does not alter the stage 
 Involvement of nodes not taken into account 
 Vulval involvement not mentioned in staging 
 Inguinal lymph nodes not taken into account 
 Involvement of urethra does not alter the stage. 
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EVOLUTION IN THE MANAGEMENT OF CERVICAL CANCERS 
 Before the discovery X-rays, all Gynecological malignancies were managed 
with radical surgery and pelvic exenterations in the 18th century. The discovery of X-
rays by Wilhelm Conrad Röntgen in 1985 revolutionized the management of cancers, 
particularly cervical cancer. Radiotherapy has been used in the management of 
cervical cancer since the early 1900. Over the years treatment planning techniques 
have evolved along with the equipment used in therapy and planning. RT techniques 
have evolved from the single direct field whole pelvic radiation to the 2 opposing AP-
PA / 4 field box technique and the more recent Image guided / Adaptive radiotherapy 
in the management of locally advanced cervical cancer. Based on randomized trials 
and meta-analysis platinum based Chemotherapy along with radiotherapy has become 
the standard of care for locally advanced cervical cancers. Earlier Locally advanced 
FIGO Stage III.B were managed with a palliative intent of treatment but now with the 
advances in management and multimodality management, more and more cases are 
being managed with a curative intent. Though the incidence of locally advanced 
FIGO Stage III.B cervical cancers have drastically declined over the past few decades 
in the western population, a majority of cases in the developing countries like India 
present in the locally advanced stage. There are not many advances in the 
management of locally advanced cervical cancers in the last decade with emphasis on 
III.B advanced disease. In this article we will attempt to explore the strategies to 
improve the outcome of Advanced III.B disease. 
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CHEMOTHERAPY 
 The use of chemotherapy in the management of cancer came much later than 
radiotherapy when in World war II it was found that nitrogen mustard reduced the 
white blood counts. Now based on the results of 5 randomized trials the NCI 
proposed that cisplatin based chemotherapy concurrent with radiotherapy prolonged 
survival in patients with locally advanced cervical cancer. 
 The mechanism of the efficacy of chemotherapy is thought to be due to 
radiosensitization of tumour cells, direct cytotoxic effect and control of subclinical 
metastasis [12]. 
 A meta-analysis of 13 trials that compared chemoradiation to only radiotherapy 
showed a 5 year survival improvement of 6% with chemoradiation (hazard ratio 0.81, 
p<0.001). This resulted in reduction of both local and distant failure.This meta-
analysis also suggested that with increasing stage, the benefit of chemotherapy 
decreased. The 5 year survival benefit reduced by 3% with Stage III.B and IV.A 
disease [13].  
 An analysis by Nugent et al showed that the number of cycles of chemotherapy 
was independently predictive of progression free survival and Overall survival. This 
study reiterated that advanced stage, longer treatment time to complete radiotherapy 
and absence of brachytherapy were associaced with decreased overall survival and 
progression free survival (p<0.05) [14].  
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Chemotherapy has been studied in the Neo adjuvant setting, the concurrent 
setting and the adjuvant setting.  
 Adjuvant Chemotherapy in Locally advanced cervical cancer was assessed in a 
phase III Randomized study comparing concurrent Chemoradiation with cisplatin /  
gemcitabine followed by adjuvant gemcitabine / Cisplatin versus concurrent 
chemoradiation. The 3 year progression free survival was 74.4% vs 65% favoring the 
adjuvant chemotherapy arm (86.5% vs 46.3%) which also included 2 deaths due to 
treatment related toxicity [15]. 
 Results published by Tseng et al was a randomized trial of advanced cervical 
cancer patients comparing chemoradiation using cisplatin, vincristine and bleomycin 
with only radiotherapy which showed that the overall Disease free survival and 
actuarial survival at 3 years were 51.7% and 61.7% in the chemoradiation group and 
53.2 and 64.5% in the only radiotherapy group. Treatment related toxicity was more 
in the chemoradiation group (36.7% Vs 17.7%). In conclusion, multi agent 
chemotherapy was not superior to only radiotherapy for patients with advanced 
cervical cancers [16].  
 Due to the poor results with chomoradiation in locally advanced cervical 
cancers, Souhami et al investigated the option of Neo-adjuvant chemotherapy in a 
randomized trial using BOMP (Bleomycin, vincristine, mitomycin C and Cisplatin) 
when compared with only radiotherapy. Complete response was seen in 32.5% vs 
47% favoring only radiotherapy which translated to 5 year overall survival of 23% 
with neoadjuvant chemotherapy vs 39% with only radiotherapy. The chemotherapy 
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related toxicity profile was severe with neoadjuvant chemotherapy and the authors 
concluded that neoadjuvant chemotherapy adversely affects survival in Stage III.B 
cervical cancer and is associated with unacceptable toxicity [17].  
 Another study on Neo-adjuvant chemotherapy by Kumar et al showed 
contrasting results with bleomycin, ifosfamide-mesna and cisplatin when compared 
to only radiotherapy showed a 32 month survival of 50 % and 27 % favoring the 
neoadjuvant chemotherapy arm. While 2 patients died of chemo related toxicity, there 
was no difference in the radiotherapy related toxicity between the two groups [18]. 
 
RADIOSENSITIZERS   
 Agents that sensitize the tumour cells to radiation are called radio-sensitizers. 
These agents promote the fixation of free radicals caused by radiation at the 
molecular level. The damaged molecules undergo biochemical reactions which 
prevent the repair of radiation induced cell damage. Free radicals are seized by the 
electron affinity of radio-sensitizers, making the molecules incapable of repair. 
 
 HYPERBARIC OXYGEN 
            The radiosensitivity of cells increase when exposed to oxygen. The 
 oxygen interacts with the free radicals produced by ionizing radiation to 
 produce peroxy radicals and hydrogen peroxide which cause structural 
 damage. Hyperbaric oxygen is delivered by placing the patient in a high 
 pressure oxygen tank delivering 100% oxygen during every fraction thus 
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 increasing the oxygen tension of the tumour. 
           In a randomized trial of 320 patients (Stage III & IV.A) by Watson et al, 
 the 5  year survival was 33% vs 27% in the control group (p=0.08). The rate of 
 local  recurrence was 33% in patients treated with hyperbaric oxygen and 53% 
 in patients who received normal air [19].  
            Advanced cervical cancers treated with radiotherapy and oxygen or 
 radiotherapy alone were reviewed by Dische et al. Analysis of the randomized 
 study showed that the local tumour control without hyperbaric oxygen was 
 poor which was seen in the survival (p=0.042) [20]. 
   Other trials by Fletcher and a review article by Dische et al showed that 
 there was no benefit with hyperbaric oxygen and the toxicity profiles were 
 significantly more in patients treated with hyperbaric oxygen.                                                               
  Although some of the results of randomized trials are promising, the  
 delivery of hyperbaric oxygen during radiation is very inconvenient with a 
 rise in the toxicity profile. Hence more studies are required with head to 
 head comparison with chemotherapy to come to any definite conclusion. 
 CISPLATIN 
   In 1961, Dr Barnett Rosenberg found that exposing an electric field on 
bacteria resulted in a change in their morphology which was not because of the 
electric field but due to the electrolysis products produced by platinum 
electrodes. Cisplatin a platinum compound interacts preferably at the N7 
position of purine analogues forming interstrand and intrastrand cross links 
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which cause DNA damage and block cell division resulting in apoptotic cell 
death.                                                                                                                        
         The NCI proposed that Cisplatin based chemotherapy along with radiotherapy 
prolonged survival in locally advanced cervical cancer based on the findings of 5 
randomized trials and meta-analysis. 
 CARBOPLATIN  
  In stage III.B cervical cancers, the disease extends upto the lateral pelvic 
side walls or may present with Hydro-ureteronephrosis. Such patients have a 
high chance of renal compromise especially after they are exposed to contrast 
for spiral CT or pyelogram. These patients may not tolerate cisplatin as it is 
known to be nephrotoxic. In these situations Carboplatin which is a platinum 
analog may be used as an alternative to Cisplatin to prevent further damage to 
the kidneys.  
   Studies by Katanyou et al and Cetina et al have shown that the use of 
Carboplatin is better tolerated with less side effects and may have reduced 
efficacy when compared to weekly Cisplatin [21,22]. 
 
 MITOMYCIN – C 
  It is a naturally occurring antitumour quinone derived from 
Streptomyces caespitosus (a strain of actinomyces). Most of the studies with 
Mitomycin C (MMC) have been along with 5 FU which produced a lot of 
Gastro-intestinal morbidity.  
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  Roberts et al published the results of a randomized trial using MMC 
alone along with radiotherapy in patients with locally advanced cervical cancer 
compared with radiotherapy alone. The 4 year disease free survival favored the 
MMC radiotherapy arm (71% vs 44%) which was not statistically significant. 
The same results were seen in the local control and systemic control. A 
subgroup analysis showed that MMC improved the disease free survival in 
more advanced stages [23]. This sub group analysis is of principle importance 
as the benefit of Cisplatin reduces with increasing stage and this benefit is less 
than 5% in locally advanced FIGO Stage III.B cervical cancer. In such cases, 
MMC may be a good option although randomized head to head trials are 
required to substantiate this. The use of MMC along with 5 FU produced a lot 
of toxicity but MMC used as a single agent was well tolerated. 
 
 EPIRUBICIN 
  It is an analog of anthracyclin. Bulky locally advanced cervical cancer, 
randomized to receive only radiotherapy and Concurrent Epirubicin followed 
by adjuvant chemotherapy were analyzed. The disease free survival was 
statistically significant with Epirubicin although the local control rates were 
comparable in both arms. The author concludes that the benefit is likely to be 
due to the adjuvant chemotherapy [24].   
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 GEMCITABINE                        
    It is one of the main radiosensitizers studied around the world. Studies 
have shown that gemcitabine compliments both radiation and cisplatin. In a 
phase II study by pattaranutaporn et al, gemcitabine was delivered at 300 
mg/m2 weekly during radiotherapy for 5 weeks in patients with FIGO Stage 
III.B cervical cancer. This regiment was tolerated well. At follow up, CR was 
achieved in all except 2 and at a median follow up of 20 months the DFS and 
OS were 84% and 100% respectively [95]. Though gemcitabine has shown 
excellent local control rates, the toxicity when combined with cisplatin is on 
the higher side as gemcitabine sensitizes both radiation and cisplatin. This was 
seen in a study by Alvarez et al [96, 97].                
    In a phase III randomized study comparing cisplatin with gemcitabine 
and radiotherapy followed by adjuvant cisplatin and gemcitabine versus 
concurrent cisplatin with radiotherapy in locally advancer cervical cancer 
showed significantly improved progression free survival (p=0.029) and overall 
survival (p=0.0224) with the adjuvant chemotherapy arm with manageable 
toxicities [98]. 
 BEVACIZUMAB 
RTOG 0417 was a phase II study which evaluated the efficacy of 
bevacizumab in 49 patients with locally advanced cervical cancer. The three 
year disease free survival and overall survival were 68.7% and 81.3% 
respectively with no serious adverse events [99]. 
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HYPERTHERMIA 
 Many randomized trials analyzing the use of hyperthermia combined with 
radiation and chemotherapy have shown clear and significant clinical benefits. At 
temperatures >40 degree Celsius direct cytotoxicity occurs as a result of protein 
denaturation. Radiotherapy and chemotherapy are least effective in hypoxic, acidotic 
and nutrient deprived areas of the tumour where hyperthermia specially acts. 
 The Dutch deep hyperthermia trial showed a significant improvement in 
survival and local control when radiotherapy was combined with hyperthermia in 
pelvic malignancies. The benefit was more pronounced in locally advanced cervical 
cancers [25].  
 In cervical cancers, hyperthermia is administered a maximum of 5 sessions 
during the course of radiation and delivered 1 to 4 hours after radiotherapy to avoid 
thermotolerance.  Experimental studies have shown that hyperthermia interferes with 
the repair of DNA damage in cells which potentiates the effect of radiotherapy. 
Vasodilatation also causes increased blood flow to the tumour which causes better 
oxygenation of tumour cells and better response to radiotherapy.  
 The Dutch deep hyperthermia trial compared radiotherapy with hyperthermia 
to radiotherapy alone in locally advanced cervical cancers. The rate of complete 
response with hyperthermia was 83% when compared to 57% in the only 
radiotherapy group. The 5 year pelvic control rate was 61% vs 37% in favor of 
hyperthermia and the 12 year pelvic control rate was 56% vs 37% which was 
statistically significant (p=0.01). The overall survival was 37% with hyperthermia 
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when compared to 20% with only radiotherapy. Almost 80% patients in this study 
were locally advanced stage III.B and IV.A. More importantly hyperthermia did not 
increase the radiation induced toxicity.  
 Harima et at compared only radiotherapy to hyperthermia and radiotherapy in 
Stage III.B cervical cancers. The complete response, 3 year overall survival and 
disease free survival with only radiotherapy was 50 %, 48.1% and 45% respectively 
compared with 80%, 58.2% and 63.6% with hyperthermia. The results were not 
statistically significant and the toxicity profiles of both arms were comparable [26]. 
 The Cochrane database review of 6 randomized trials showed a higher 
complete response rate, lower rate of local recurrence and improved overall survival 
with hyperthermia and the toxicity profile was comparable to that of only 
radiotherapy [27]. 
 In conclusion, hyperthermia has shown promising results in locally advanced 
cervical cancers where the benefit of chemotherapy is minimal. The toxicity profile in 
patients receiving hyperthermia is low and it can be used as an alternative to patients 
who are not fit for chemotherapy due to varied reasons. The drawback of 
hyperthermia is that it is a tedious process which needs improvements in treatment 
planning which offers precision and controllability rather than the present empirical 
approach. 
 
 
 
27 
 
BRACHYTHERAPY   
 Brachytherapy for cervical cancer was first mentioned in the Journal of 
American medical association as early as 1902. It describes the use of radium as local 
application in some cases of internal or quasi internal cancers such as that of cervix 
uteri [28]. 
 In 1903, James Morton from New York presented various apparatus for radium 
treatment within the vaginal cavity and reported 3 cases of cervical cancer or 
recurrent cervical cancer treated with radium which showed better results than 
treatment with X-rays [29,30]. 
 The advances in equipment, technique and the precision in treatment delivery 
have been exemplary since then but the underlying message remains the same that       
'Brachytherapy is an immortal art' and external beam radiotherapy may never replace 
brachytherapy.  
 Brachytherapy plays a vital role in the management of cervical cancer and 
evidence confirms that the use of brachytherapy for dose escalation after external 
beam radiotherapy significantly improves survival in locally advanced cervical 
cancers.  
 Intracavitary application may be challenging in bulky locally advanced FIGO 
Stage III.B disease where there may be insufficient tumour regression, persistant 
parametrial involvement, distal vaginal involvement and vaginal narrowing. In such 
situations, intracavitary brachytherapy may not adequately cover the residual tumour 
while maintaining dose constraints to the organs at risk [31]. This has led to the need 
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to explore other strategies for dose escalation like IMRT and SBRT [32-34]. Although 
these technological advances have shown to be promising, they have resulted in 
inferior survival when compared with brachytherapy. 
 In 2014, B.S.Gill et al published the National cancer data base analysis on the 
impact of new technological advances in radiotherapy, which reviewed 7000 patients 
who were treated between 1998 and 2011. The review demonstrated a decline in the 
use of brachytherapy over the years however the median survival with brachytherapy 
was 70.9 months while the median survival with IMRT and SBRT boost was only 
23.8 months. Also, the IMRT and SBRT boost increased the risk of death more than 
the lack of chemotherapy [35]. 
 Syed et al demonstrated that at a median follow up of 51 months, the local 
control rate was 73% with LDR brachytherapy for locally advanced cervical cancers 
[36]. 
 As brachytherapy has shown to improve local control and survival when 
compared to EBRT boost, Interstitial brachytherapy may be ideal in certain situation. 
Interstitial brachytherapy, although feasible is an invasive procedure which requires 
technical expertise and may cause more treatment related morbidity.  
 With HDR Interstitial brachytherapy Neeta Kannan et al showed that the 2 year 
acurial local control, DFS, OS and Grade III toxicities were 61%, 43%, 53% and 10% 
respectively [37]. 
 Evolution of brachytherapy planning has led to 3D image guided 
brachytherapy which allows volumetric optimization in improving the coverage of 
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tumour by sparing critical organs which may potentially reduce toxicities and 
increase local control. 
 Studies that compared 2D and 3D image guided brachytherapy showed that 2D 
radiograph based brachytherapy overestimates the tumour dose. The average volume 
prescribed dose coverage was Stage I.B.1 – 98.5%, Stage I.B.2 – 89.5%, Stage II.B – 
79.5% and 59.95% for Stage III.B. This shows that for advanced stages, 2D 
brachytherapy becomes less reliable [38]. Similarly other studies showed that 2D 
based brachytherapy underestimates rectum and bladder dose compared to 3D based 
brachytherapy by 1 to 5 fold [39-42]. 
 Adequate coverage of large volume disease may be challenging with 
intracavitary brachytherapy and may require image guided intracavitary/interstitial 
brachytherapy(vienna applicator) to improve local control by creating an asymmetric 
dose distribution and dose escalation. 
 This was reiterated by the vienna group which showed that the 3 year acturial 
overall survival was 28% for tumours more than 5 cm prior to the era of image based 
brachytherapy compared to 58% (p=0.003) with image based brachytherapy [43,44]. 
 
PROPHYLACTIC PARA-AORTIC RADIOTHERAPY 
 Irradiation of the para-aortic region when there are no significant para-aortic 
nodes, in patients who are likely to fail or have a high chance to fail in the para-aortic 
region is called prophylactic para-aortic radiotherapy. 
 In a randomized trial by Haie et al and EORTC on prophylactic para-aortic 
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radiotherapy in 441 patients with locally advanced cervical cancer, there was no 
difference in survival, local control or rate of distant metastasis but the rate of distant 
failure and failure in the para-aortic region without a pelvic recurrence was 
significantly more without prophylactic para-aortic radiotherapy. The rate of severe 
complications was more in the patients who received prophylactic para-aortic 
radiotherapy (9% vs 4.8%) [100]. 
 In an assessment of 758 patients by Huang et al, dense parametrial infiltration 
(p=0.002), pelvic lymph nodes (p=0.007) and SCC-Ag level more than 40 
ng/ml(p<0.001) were factors that independently predicted para-aortic nodal relapse. 
Serum CEA value more than 10 prior to treatment was also predictive of para-aortic 
relapse [101]. Thus the decision on prophylactic para-aortic radiotherapy needs to be 
made based on several factors and the benefits need to be weighed against the side 
effects and toxicity profile associated with prophylactic para-aortic radiotherapy. 
 
ALTERED FRACTIONATION IN CERVICAL CANCER 
 In cervical cancer, altered fractionation is known to cause radiotherapy related 
morbidity due to rapidly renewing cells in the bowel. These are some of the altered 
fractionation schedules that were tried in locally advanced cervical cancer. 
 
HYPERFRACTIONATION AND ACCELERATED FRACTIONATION  
 Delivering the same Total dose as conventional regimen in twice as many 
fractions half the OTT by treating twice a day in the same overall treatment time as 
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the conventional regimen is defined as 'Pure Hyperfractionation'. 
 Impure hyperfractionation is the increase in Total dose (TD) and sometimes a 
longer overall treatment time as well as more fractions, delivered twice a day. 
 The intent is to achieve better tumour control, reduce late side effects and same 
or slightly increased early effects. The basic aim of hyperfractionation is to separate 
early and late effects.  
 Delivering the same Total dose as conventional regimen in half the OTT by 
treating two or more fractions per day is called 'Pure accelerated fractionation'. The 
intent is to reduce the repopulation of rapidly proliferating tumours. In practice it is 
either necessary to introduce a break in the middle of treatment or reduce the total 
dose slightly with acute effects as the limiting factor. 
 In a phase II study by Macleod et al, 61 patients with LACC were treated with 
accelerated hyperfractionation with 1.25 cGy delivered 2 times a day with atleast 6 
hours gap between treatment to a total dose of 57.5 Gy followed by LDR 
brachytherapy or reduced field boost to a smaller volume. 30 patients developed 
acute toxicities requiring medication. The 5 year OS was 2 % and the relapse free 
survival was 36%. 7 patients developed severe late complications requiring surgical 
intervention and 5 patients had to undergo total hip replacement [45]. 
 In a randomized study of 30 patients by Viswanathan et al, 15 patients received 
hyperfractionation and 15 patients received conventional fractionation. 2 patients in 
the study arm and 8 patients in the control arm developed recurrence at 5 years 
(p=0.04). Grade II/III delayed bowel complication was more with hyperfractionation. 
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(p=0.0006) [46]. 
 In a phase II trial of hyperfractionation by RTOG (8805), 81 patients were 
treated with 1.2 Gy per fraction, twice daily delivered 6 hours apart followed by 
brachytherapy in locally advanced cervical cancers. In stage III/IV.A disease, the 5 
year cumulative rate of grade 3 or 4 late effects was 12% [47]. 
  
CHART – CONTINUOUS HYPERFRACTIONATED ACCELERATED RT 
 In a pilot study by Biswal et al, 50 patients with locally advanced cervical 
cancer were treated with 1.4 Gy per fraction deliver 3 times a day with an interval of 
6 hours between treatment for 10 days (30 fractions to deliver 42 Gy) without a 
break, followed by 2 HDR brachytherapy. At the end of treatment 48 % had complete 
response, 40%  had partial response and 8% had stable disease. While the local 
recurrence rate was 32%, 16% developed metastatic disease. Late morbidity was seen 
in 4 patients. Thus this regimen was well tolerated with optimal local control rates 
[48]. 
 The advantages of this schedule is the short treatment time which is preferred 
by patients, acute reactions develop after the completion of treatment, late effects are 
minimized and good local control with reduction in overall treatment time. The 
disadvantage is that it is tedious due to treatment of 3 fractions per day which may be 
challenging in a high patient load centre. 
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SIMULTANEOUS INTEGRATED BOOST 
 Simultaneous integrated boost (SIB) is an IMRT technique that allows the 
planning and irradiation of different targets at different dose levels in a single 
treatment session instead of using sequential treatment plans. It is used to increase the 
dose to the boost volume while keeping the dose to the elective volume at a lower 
level. This technique was initially used in head and neck cancers and prostate cancer 
as early as 2000 and has been in use in cervical cancer since 2009 [49-51].  
 The advantage of SIB is to deliver higher dose to the tumour while reducing 
the overall treatment time (OTT) which may translate into improvement in local 
control [52-54]. Reducing the OTT limits the effect of accelerated tumour 
repopulation.  
 Due to the non uniform beam intensity and steep dose gradients in IMRT, 
geographical miss or high dose to organs at risk is a possibility due to organ motion 
during or between treatments. Studies have shown that interfraction uterine motion 
can be up to 4.8 cm and interfraction cervical motion can be 1.9 cm [55]. 
Dosimetrically some studies have shown that SIB-IMRT has advantages over 
sequential IMRT in dose escalation. These studies state that in SIB IMRT the dose 
distribution is even more conformal resulting in better coverage of the boost volume 
while sparing non target tissues [56-58].   
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OVERALL TREATMENT TIME (OTT) 
 In cervical cancer, extension of overall treatment time has a negative effect on 
local control and survival [59-63]. The reason for this may be due to accelerated 
repopulation of tumour cells during fractionated radiotherapy [64,65]. Hence 
reduction in the OTT can improve local control. OTT has been stated as one of the 
most important prognostic factors and pelvic failure rate is approximately 1% per day 
of extension of treatment time beyond 30 days [66]. The 5 year survival in a study by 
Girinsky et al with treatment time less than 55 days when compared to more than 55 
days was 65% and 54% (p=0.03) and the pelvic control rates were 87% and 72% 
respectively (p=0.006). To add to this the survival reduced by 0.6% per day and 
pelvic control rate by 0.7% per day for all stages [67]. 
 In a study by Mandal Abhijit et al (2007) it was found that patients with Stage 
III Carcinoma cervix had higher local control rates (100% Vs 76.5 %) which was 
statistically significant and a 5 year DFS rate of 100% vs 68.6% when the Overall 
treatment time of less than 50 days was compared with treatment time more than 50 
days [68].  
 Sanjay singh et al's assessment of Stage III patients showed comparable local 
control rates of 82.6 % and 88.2 % with OTT less than or equal to 50 days when 
compared to OTT more than 50 days. Across all stages, the local control rate was 
statistically significant (p<0.005) [69]. 
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 The aim of accelerated radiotherapy is shortening of OTT by delivering more 
than 5 fractions per week using standard fractionation (pure accelerated fractionation) 
or using a larger dose per fraction five times a week (hybrid accelerated 
fractionation). These studies are ideal for chemical modulation of radiation sensitivity 
like hypoxic cell sensitizers which require high concentration of the compound in the 
tumour site at the time of exposure to radiation. 
 Yang et al reported that Accelerated regimes significantly increase tumour 
control probability for tumours with clonogenic cell doubling time (Tpot) smaller than 
3 days [70]. 
 Tk is the lag time defined as the time between the start of treatment and the start 
of repopulation [70, 71]. It is reported that on the assumption of  Tk to be 30 days, to 
counterbalance tumour repopulation and keep tumour control rates unchanged for 
OTT's upto 55 days, a dose increment of 0.6 to 0.7 Gy per day is required [72, 73]. 
 Acute responding normal tissues show a proliferative response to radiation 
induced reproductive cell death as early as the 1st week of treatment [74]. Acute 
mucosal reaction follow cellular supression and regression. 
 In a report by Denham et al, the onset of adverse effects (Grade II & III) was 
higher during accelerated regimens over 3 ½ weeks compared to conventional 
fractionation schedules over 7 weeks [75]. 
 OTT plays a negligible role in producing late reaction [76, 77]. Late 
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responding normal tissues have a slow rate of cell renewal, that functional damage 
and depletion of cells are not apparent until after the end of conventional fractionated 
radiotherapy eg : onset of repopulation for spinal cord ranges from 120 to 150 days 
[78, 79]. This is for genuine late effects. On the other hand consequential late effects 
which are caused due to the severity of acute side effects are affected by OTT [80]. 
 Randomized studies showed that accelerated fractionation is associated with a 
high rate of severe mucosal sequelae [77] and there was a correlation which was 
significant between acute mucosal and late effects [81]. 
 
FRACTION SIZE 
Radiobiologically tumours and acute responding normal tissues are less sensitive to 
change in fraction size compared to late responding tissues [77]. The effect of change 
in fraction size for different tissues can be quantified based on the α/β ratio. 
 The survival curves for acute responding tissues and tumours (high α/β ratio) is 
more linear while the survival curve for late responding tissues (low α/β ratio) is 
significantly curved. Hence the effect of fractionation is more in late responding 
tissues than acute responding tissues or tumour tissue. Bothe the Field size and OTT 
both determine the response of acutely responding tissues. 
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Biological Effective Dose (BED) 
 It is the quantity by which different fractionation regimens are compared. 
BED = Total dose x Relative effectiveness. 
 In the LQ model,  α represents the loge of cells killed per Gy for the linear 
portion on the curve and β represents the loge of the cells killed per Gy squared.  α/β 
is the dose at which the linear and quadratic components of cell killing are equal. 
Biological effect E = αD + βD2      (where D is the Total dose) 
 For a fractionated schedule, where n is the number of fractions and d is the 
dose per fraction, 
Biological effect E = n(αd + βd2) 
ie. E = nd(α + βd) 
E = (α)(nd) (1 +  d  ) 
                         α/β 
number of fractions n multiplied by the daily dose d gives the total dose D. 
ie. E =  α (Total dose) (Relative effectiveness) 
where Relative effectiveness = 1 +  d   
                                                        α/β 
If this equation is divided by α throughout, 
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   E  .  = Total dose x Relative effectiveness,      
   α 
 
and this   E  . = is the Biological Effective dose. 
               α 
 
Thus,                           BED = nd(1 +  d  ) 
                                                            α/β 
 The use of this equation is justified only if there is complete repair between 
two successive fractions and no proliferation during treatment. Hence, this formula 
can be used only for late responding tissues while using SIB-IMRT, whereas for 
acutely responding tissues and tumour tissues, the cell proliferation should be taken 
into account to calculate the BED [82]. 
Fowler formulated that [83], 
Relative effectiveness = 1 +  d                  ln2    T – Tk 
                                                                      α/β               ndα       Tpot 
where  
Tpot is the potential doubling time 
Tk is the time of onset of proliferation    and 
T is the Overall treatment time (OTT). 
Relative effectiveness =  nd( 1 +  d  )                 ln2    T – Tk 
                                                                                  α/β                  ndα       Tpot 
 While treating multiple fractions per day, an interfraction interval should be at 
least 6 hours to ensure a complete repain of sublethal damage after each dose. This 
time is sufficient for many normal tissues to fully recover between fractions. 
 
39 
 
DOSE RESPONSE RELATIONSHIP OF EARLY AND LATE RESPONDING 
TISSUES 
 
 The response of early and late responding tissues change with different 
fractionation. Late reactions are more severe if larger dose per fraction is given over 
fewer fractions, even though early reactions are matched by adjusting the total dose. 
This is attributed to the differences in repair capacity or the shape of the shoulder of 
the underlying dose-response curves. For late responding tissues, the dose response 
relationship is more curved than early responding tissues. In terms of the LQ model, 
α/β ratio is the dose at which the linear and quadratic components are equal. The α/β 
ratio is large for early responding tissues and tumours, as a result α dominates at low 
doses. The α/β ratio is small for late responding tissues, so that the β term has an 
influence at low doses. 
 If a fractionation is changed from many small doses to a few large doses and 
the total dose is titrated to produce equal early effects, the treatment involving 
large doses in few fractions result in more severe side effects. 
 In hyperfractionation, where the doses are delivered per day for 6 to 7 weeks, 
the late effects appear to be greatly reduced if the total dose is titrated to 
produce equal or slightly more severe acute effects. 
 The isoeffect curves are steeper for late effects than acute effects. 
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ACCELERATED REPOPULATION 
 Surviving cells or clonogens in a tumour that are triggered by cytotoxic agents 
like radiotherapy divide faster than before. This is called Accelerated repopulation. 
 In an analysis by Withers, it was found that clonogen repopulation accelerates 
at about 28 days after initiation of RT in a fractionated regimen. A dose increment of 
0.6 Gy per day is required to compensate for this repopulation. This increment is 
consistent in a 4 day clonogen doubling doubling rate compared with a median of 
about 60 days of unperturbed growth. 
 
CONCOMITANT BOOST 
 Concomitant boost using conformal therapy incorporates the benefits of SIB-
IMRT by reducing the overall treatment time and dose escalation to the boost region 
while sparing the normal tissues using field in field forward planning technique. 
 Studies have shown that dose escalation to the tumour and reduction in the 
overall treatment time improves the local control. Dose escalation to the tumour also 
increases the dose received by the organs at risk like rectum, small bowel and bladder   
causing acute and late toxicities. A highly conformal IMRT dose distribution allows 
significant sparing of these organs at risk. In standard fractionation, dose escalation to 
the tumour can be achieved by increasing the number of fractions which increases the 
overall treatment time. The increase in overall treatment reduces the local control. 
Dose escalation to the tumour without increasing the overall treatment time can be 
achieved by Concomitant boost or Simultaneous integrated boost. There have been 
41 
 
few studies where Simultaneous integrated boost or concomitant boost has been 
achieved using IMRT technique which showed satisfactory local control with 
acceptable morbidity by dose escalation to the tumour. SIB – IMRT plans are less 
likely to cause uncertainties in planning or delivery as it involves the same treatment 
plan for the entire course of treatment. 
 In April 2016, Waqar M Haque published and article in the International 
journal of cancer and oncology on SIB using conformal therapy for cervical cancer. 
21 patients were treated with 45 Gy to the pelvis and 50 Gy to the boost volume in 25 
fractions. 61 % patients were locally advancer III.B/IV.A. The 2 year local control 
rate was 95.2% and 2 year disease free survival was 80.9%. 2 patients developed 
acute Grade III toxicity and 3 patients developed chronic Grade III toxicities. Though 
the majority of the patients were Stage III.B/IV.A, the local control rates were 
excellent with acceptable toxicities [84]. 
 In a retrospective feasibility study on the impact of organ motion and tumour 
regression in patients treated with simultaneous integrated boost by Fernanda G 
Herrera showed that SIB required frequent re plans or adaptation of treatment plan to 
prevent increased dose to the organs at risk and reduced dose to the target volume 
[85]. 
 A prospective phase II study LARA-CC (Large field radiotherapy in advanced 
cervical cancer) where 40 Gy in 2 Gy per day for 20 days was delivered to the whole 
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pelvis along with 0.25 Gy boost to the macroscopic disease(2.25 Gy) to a total dose 
of 45 Gy which was followed by surgery. The local control in terms of pathological 
complete response was not superior to conventional treatment [86]. 
 Katrien Vandecastele et al published an article on SIB-IMAT in locally 
advanced cervical cancer. 6 patients were treated with SIB and dose escalation was 
achieved with acceptable dose to the elective lymph nodes and organs at risk [87]. 
 A study by Kavanagh et al showed that IMRT Concomitant boost can be used 
as an alternative to brachytherapy in patients who are not fit for the procedure in view 
of age and co-morbid illness with acceptable toxicity profile [88]. 
 This is a study proposing feasibility of 3D CRT to provide a higher dose 
simultaneously to the primary tumour area. The role of IMRT to simultaneously boost 
the primary is unquestionable when small volumes are considered and where more 
organs are at risk around our target. But in an advanced pelvic malignancy where the 
target volume is large and where completely avoiding the bladder base or the recto-
sigmoid septum are not recommended, 3D CRT may be tried.  
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AIM OF THE STUDY 
  To evaluate the feasibility and efficacy of concomitant boost using 3D-CRT in 
patients with locally advanced cervical cancer. 
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MATERIALS AND METHODS 
 After obtaining an informed consent 29 patients with locally advanced FIGO 
Stage III.B were enrolled with clearance from the ethics committee. All patients 
included were ECOG performance status 0 or 1 and were investigated as outpatient 
basis after a detailed history and clinical examination. A cervical punch biopsy was 
done on the first day of hospital visit.  
 INVESTIGATIONS  
-Complete blood count 
-Biochemical evaluation – RFT, LFT, Sr.Electrolytes, Creatinine clearance and 
Fasting / post prandial blood sugar. 
-Blood grouping and RH typing 
-Viral markers – HIV, HbsAg and HCV 
-ESR and Urine routine 
-Chest X-ray 
-ECG and Echocardiogram 
-Ultrasound Abdomen and pelvis 
-Cystoscopy 
 After a complete evaluation, patients were admitted for treatment. A complete 
Gynecological examination (per speculum and per vaginal) was done prior to starting 
treatment and the clinical stage was confirmed based on FIGO staging (2009). 
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INCLUSION CRITERIA 
 FIGO Stage III.B bulky disease. 
 Curative intent of treatment. 
 Fit for Brachytherapy under short GA 
 
EXCLUSION CRITERIA 
 Presence of distant metastasis 
 Prior irradiation to primary site 
 Presence of para-aortic nodes 
 Presence of bulky pelvic nodes 
 > 70 years 
 Medical renal disease 
 Involvement of lower third of vagina 
 Other histologies-neuroendocrine, sarcoma, lymphoma. 
 Decision on chemotherapy was based on age, general condition of the patient, 
nutritional status of the patient and associated co-morbid illness. 
 Prior to the start of treatment, the patients and attenders were extensively 
counseled regarding the precautions that need to be taken during the course of 
treatment with an emphasis on dietary habits. 
 Concurrent Chemoradiation was delivered with External beam radiation to the 
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pelvis along with weekly cisplatin (40 mg/m2) for 5 cycles, followed by reassessment 
for brachytherapy. 
 CT simulation was done on a flat couch in supine position. Although the ideal 
method to simulate and treat in pelvic malignancies would be to use a Vac-Lok or in 
prone position with full bladder, our patients were simulated after complete voiding 
and consumption of a fixed dose of 200 ml water and CT simulation was done after 
20 min and this was carried out every day during the course of treatment. CT 
simulation was done with a thickness of 5mm without oral or IV contrast extending 
superiorly from the liver upto mid thigh region. 
 After CT simulation, the images were acquired into the treatment planing 
system and after registration, the target volumes and organs at risk were contoured 
based on the RTOG guidelines.  
 External beam radiotherapy will be delivered with 49.4 Gy EBRT to whole 
pelvis(apart from the primary GTV) and concomitant boost to the primary GTV TD 
54.6 Gy followed by intracavitary brachytherapy.  The target volumes included the 
GTV(Gross tumour volume), CTV (Clinical target volume) and PTV (Planing target 
volume). 
 Treatment planning was done with forward planning conformal therapy using 
field in field technique based on the recommendations of ICRU 83.  
 CTV  
 The clinical target volume (CTV cervix) was defined as the GTV cervix, 
corpus uteri, bilateral parametrium, involved nodes and upper third of vagina. In 
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cases with vaginal involvement, the CTV cervix was extended 2 cm below the 
vaginal involvement. The planning target volume of the CTV cervix (PTV cervix) 
was obtained using a three dimensional anisotropic expansion of 10, 7, and 7 mm in 
the antero-posterior, left-right, and superoinferior direction, respectively. 
 The elective lymph nodal areas included the common, internal and external 
iliac nodes, the obturator and presacral region. Using a three dimensional expansion 
of 2 mm and 7 mm around nodes, respectively, the CTV nodes and PTV nodes will 
was created.  
DOSE PRESCRIPTION 
 PTV 1 (Whole pelvis apart from primary GTV)- 1.9 Gy per day, 5 fractions per 
week for a total 26 fractions, receiving TD 49.4 Gy.  
 PTV 2 (Primary GTV)-  2.1 Gy per day, 5 fractions per week for a total of 26 
fractions was delivered concomitantly to receive TD 54.6 Gy. 
Rectum – Dmean < 44 Gy and Dmax < 54 Gy. Rectal volume receiving 40 Gy (< 40 %). 
                Rectal volume receiving 45 Gy (78-85 cm3) 
Small bowel – Dmax < 50 Gy and Dmean < 33 Gy. Volume receiving 35 Gy < 35%. 
                Volume receiving 45 Gy < 14% and < 360 cm3. 
Bladder – Dmax and D50 < 50 Gy. 
 3D-CRT was delivered in 26 fractions over 5 to 6 weeks, 5 fractions per week. 
An on board image was taken on Day 1 after applying the field shift for confirmation 
of patient position and this was repeated every week.  
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BEAM ARRANGEMENT  
 8 main fields were used of which 4 (AP/PA and 2 lateral fields)were used for 
the whole pelvis and 4(AP/PA and 2 lateral fields) were used for the boost volume.  
BEAM EYE VIEW OF THE PELVIC FIELD(4940 cGy) 
 
   
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
ANTERIOR FIELD 
RIGHT LATERAL 
POSTERIOR FIELD 
LEFT LATERAL 
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BEAM EYE VIEW OF THE BOOST FIELD 5460cGy 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANTERIOR FIELD 
RIGHT LATERAL FIELD 
LEFT LATERAL FIELD 
POSTERIOR FIELD 
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DOSE DISTRIBUTION COLOUR WASH AND BEAM GEOMETRY IN AXIAL, 
CORONAL AND SAGITAL PLANE 
VOLUME RECEIVING 4940 cGy 
                 
 
 
AXIAL SECTION SHOWING VOLUME RECEIVING 4940cGy 
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DOSE DISTRIBUTION COLOUR WASH AND BEAM GEOMETRY IN AXIAL, 
CORONAL AND SAGITAL PLANE 
VOLUME RECEIVING 5460 cGy 
                
 
 
AXIAL SECTION SHOWING VOLUME RECEIVING 5460cGy 
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DOSE VOLUME HISTOGRAM SHOWING ADEQUATE COVERAGE OF 
TARGET VOLUMES 
  
 
 
  
 
 
 
 
 
 
    
 
 
 
 
All patients were under admission during the entire course of treatment and 
they were assessed everyday prior to treatment. Treatment related morbidity was 
assessed based on the CTCAE ver 4.0 and RTOG grading of acute toxicity. 
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RTOG / CTCAE 4.0 GRADING OF ACUTE TOXICITY [89] 
TOXICITY GRADE I GRADE II GRADE III GRADE IV GRADE V 
SKIN Faint 
erythema or 
dry 
desquamatio
n 
Moderate to 
brisk 
erythema. 
Moist 
desquamatio
n in skin 
folds 
Moist 
desquamatio
n inareas 
other than 
skin folds 
Necrosis or 
ulceration 
involving 
full 
thickness of 
dermis. 
Spont. 
bleeding 
Death 
PROCTITIS Rectal 
discomfort. 
No 
intervention 
required 
Blood or 
mucus 
requires 
intervention.  
Urgency and 
incontinance 
limiting self 
ADL 
Life 
threatening 
consequence
s. Urgent 
intervention 
Death 
DIARRHEA < 4 episodes 
per day  
4-6 episodes 
per day 
> 7 episodes 
per day 
requiring 
hospitalizati
on 
Life 
threatening 
consequence
s. Urgent 
intervention 
Death 
VOMITING 1-2 episodes 
separated by 
5 minutes 
3-5 episodes 
per day 
> 6 episodes 
requiring 
hospitalizati
on 
Life 
threatening 
consequence
s. Urgent 
intervention 
Death 
CYSTITIS Microscopic 
hematuria. 
Minimal 
increase 
frequency 
and urgency 
Moderate 
hematuria. 
Moderate 
increase in 
frequency 
and urgency 
Gross 
hematuria 
requiring IV 
medication 
and 
transfusion. 
Life 
threatening 
consequence
s. Radiology/ 
operating 
intervention  
Death 
HYPO NA <LLN - 130  130-120 <120 life 
threatening 
Death 
HYPO K <LLN - 3.0 <LLN - 3.0 
Symptomatic 
3 - 2.5 
requiring 
hospitalizati 
<2.5 Life 
threatening. 
Death 
HYPO MG <LLN – 1.2 1.2 – 0.9 0.9 – 0.7 < 0.7 Death 
NEUTROPE
NIA(RTOG) 
4000-3000 
WBC's 
3000-2000 
WBC's 
2000-1000 
WBC's 
<1000 
WBC's 
Death 
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Radiotherapy was pended in case of Grade III/IV toxicity. 
 Chemotherapy was suspended/pended in patients with poor compliance or 
tolerance. The criteria to withhold chemotherapy was persistent myelosupression/ 
neutropenia Gr II/III/IV, Febrile neutropenia, dyselectrolytemia (Persistent low 
sodium/ potassium/ magnesium, Sr. sodium <120, Sr. Potassium <3.0, magnesium 
<1.0), Uncontrolled vomiting, rising renal parameters, Sensory neural hearing loss 
and Grade II peripheral neuropathy. 
 A repeat CT and re plan was done at 36 Gy to account for tumour shrinkage. A 
volumetric assessment of tumour shrinkage was done in comparison with the CT 
done prior to the start of treatment and response was assessed based on RECIST 
criteria . 
RECIST CRITERIA Version 1.1 [90] 
 Complete response (CR) is defined as the disappearance of the target lesion 
and reduction in the short axis of lymph nodes to less than 1 cm. 
 Partial response (PR) is defined as the reduction in the target volume diameter 
to least 30 % of the initial volume. 
 Progressive disease is defined as the increase in the target volume diameter to 
at least 20 % of the initial volume or appearance of new lesions. 
 Stable disease (Stable) – When the tumour has not progressed enough to be 
called progressive disease and has not shrunk enough to be called partial response, it 
is called stable disease.   
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 A complete clinical and gynecological examination was done at 30 Gy and 50 
Gy when the response to treatment, morbidity / tolerance to treatment and feasibility 
of Intracavitary brachytherapy were assessed.  
 Intracavitary application was done under aseptic precautions under short 
General anesthesia following which patients were shifted for orthogonal imaging of 
the applicator in situ followed by 2D brachytherapy treatment planning. 
 Brachytherapy planning was done as per the recommendations of ICRU 38 and 
treatment was delivered with High dose rate After loading technique using Ir 192 
(Half life 73.8 days). A minimum interval of 1 week was given between two sittings 
of brachytherapy. 
 At the end of treatment, patients were discharged with dietary advice and 
advice on local care. Oral vitamins and an ointment to be applied in the vagina were 
prescribed for vaginal dilatation and to keep the vaginal cavity patent and prevent 
adhesive vaginitis. 
 
GAMMA ANALYSIS 
 Patient specific QA (Quality assurance) is a fundamental step in treatment 
planning prior to treatment delivery, to confirm with accuracy that the planned dose is 
delivered to the patient and to identify errors in beam delivery. The commonly used 
QA is Gamma analysis which was introduced by Low et al. In this technique, the 
criteria used for evaluation was pass-fail criteria for both distance to agreement and 
dose difference. An acceptance criterion of 3 mm for distance to agreement and 3% 
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for dose difference with respect to maximum dose of the selected size was applied in 
the gamma analysis. The gamma passing rate is the percentage of the evaluated dose 
points that pass the above criteria when the passing criteria for gamma is less than or 
equal to 1. In our study the reference level of the gamma passing rate was between 
95% and 100% but all plans had a gamma passing rate between 98% and 100%.  
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RESULTS 
 29 patients with FIGO Stage III.B cervical cancer were treated between 
September 2015 and July 2016 at Cancer Institute Adyar. The median age at 
diagnosis was 46 years. While 12 patients (41.3%) were below the age of 45, 17 
patients (58.7%) were above the age of 45 with the oldest patient being 63 years. 
 
  
 
 Median age – 46 years 
 41.3% < 45 years 
 58.7% > 45 years 
 Oldest patient – 63 years 
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 3 patients were diabetics on medication and blood sugars were monitored 
weekly after initial consultation with a diabetologist. 5 patients were hypertensives on 
medication and BP was monitored twice daily and was under control. 
 
 
 As expected Squamous cell carcinoma was the commonest histology. Other 
histologies included Poorly differentiated Squamous cell carcinoma (4 patients), 
Adenocarcinoma (2 patients), Adenosquamous carcinoma (1 patient), Poorly 
differentiated adenocarcinoma / adenosquamous carcinoma with neuroendocrine 
features (1 patient) and Squamous cell carcinoma/Adenocarcinoma (1 patient). 
 Among the 29 patients, 12 patients (41.3 %) had Hydroureteronephrosis and 17 
patients had only pelvic side wall involvement.  
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Chemotherapy was delivered to 18 patients of whom only 8 patients (44.4%)  
completed the complete course of chemotherapy. Among the patients who received 
chemotherapy, 5 patients (27.7%) tolerated chemo well without any acute morbidity. 
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GAMMA  ANALYSIS FOR PLAN EVALUATION 
 All plans were evaluated with gamma analysis. The criteria used for evaluation 
was pass-fail criteria for both distance to agreement and dose difference with 
reference to maximum dose of selected slice. The parameters used were 3 mm 
distance to agreement and 3% dose difference with reference to maximum dose of 
selected slice. Among all patients the passing rate was between 98% and 100%. 
The following table and images are that of a patient’s gamma analysis in which 
290 dose points were evaluated out of the total 442 dose points. All the 290 dose 
points passed within the given parameters which is a 100 % passing rate.  
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COMPARISSON OF DOSE DISTRIBUTION SHOWING GAMMA ANALYSIS 
 
           
 
           
 
PASSING CRITERIA GAMMA < 1.0 
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CLINICAL RESPONSE AT 30 Gy AND 50 Gy 
 At 30 Gy and 50 Gy response was assessed based on gynecological 
examination using RECIST ver 1.1. 15 patients (51.7%) had partial response (PR) 
and 14 patients (48.2%) had Stable disease at 30 Gy. At 50 Gy, 21 patients (72.4%) 
had partial response (PR) and 8 patients (27.5%) had stable disease. 
 
 
 
VOLUMETRIC RESPONSE ASSESSMENT AT 36 Gy 
 A repeat CT pelvis was done at 36 Gy for all patients. A volumetric assessment  
of the gross tumour was done in the CT that was done prior to the start of treatment 
which was compared volumetrically with the assessment at 36 Gy. 21 patients 
(72.4%) had partial response (PR) and 8 patients (27.5%) had stable disease. 
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The mean reduction in volume at 36 Gy was 61.79 %. Brachytherapy was 
performed in 27 patients (93.10%) of whom 26 received Intracavitary 
brachytherapy and 1 patient received vaginal brachytherapy followed by 
intracavitary brachytherapy in the next sitting.  
RADIATION INDUCED ACUTE TOXICITY 
 Among 29 patients who received concomitant boost radiotherapy, 18 patients 
(62.06%) tolerated radiotherapy well without radiation related morbidity. Grade I 
proctitis was seen in 2 patients and Grade II proctitis in 3 patients. (Grade I/II 
proctitis 17.2%). 1 patient (3.4%) developed Grade II Nausea and vomiting. 2 
patients (6.89%) developed Grade I skin reaction and 3 patients (10.3%) developed 
Grade I Diarrhea.  
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CHEMOTHERAPY INDUCED ACUTE TOXICITY 
 27.7% patients tolerated chemo well without any acute morbidity. Among the 
patients who received chemotherapy, 3 patients received Grade III acute morbidity 
which required radiotherapy to be pended. 
 5 patients developed Grade I Chemo induced nausea / vomiting(CINV) and 1 
patient had Grade II CINV (Grade I/II CINV – 33.3%). Grade III Neutropenia was 
sees in 2 patients (11.1%) and Grade I/II neutropenia was seen in 2 patients (11.1%). 
While 5 patients (27.7%)  developed Grade I Hypokalemia, 2 patients (11.1%) 
developed Grade II Hpokalemia. 1 patient (5.5%) developed Grade III Hyponatremia 
and 1 patient (5.5%) developed Grade 1 Hyponatremia. In this analysis, 1 patient 
(5.5%) had Cisplatin induced Sensory neural hearing loss and 1 patient (5.5%) had 
Hypomagnesemia. 
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                               CHEMOTHERAPY INDUCED TOXICITY 
 
  
  
 
 
 
 
 
TREATMENT BREAKS: 
11 Patients (37.9%) had treatment breaks of more than 10 days of whom 9 
patients received chemotherapy but none of the treatment breaks were related to 
toxicity. 
 
LOCAL CONTROL 
 After completion of treatment, patients were reassessed after 6 weeks. 21 
patients (72.41%) had a complete response and 8 patients (27.5%) had residual or 
progressive disease. All 8 patients had local failure, among which 2 patients also had 
distant metastasis (para-aortic node / SCL node).  
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LOCAL CONTROL RATE 
 
 
 
 
 
 
 
 
 
 
 
Adverse factors noted among patients who had residual or progressive disease  
 3 patients had histology other than Squamous cell carcinoma, 
 5 patients had HUN at presentation 
 4 patients had stable disease at 50 Gy. 
 Brachytherapy not done in 3 patients in view of large volume disease and 
narrow vagina. 
 5 patients had treatment breaks of more than 10 days.  
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DISCUSSION 
 The incidence of locally advanced cervical cancer is on the decline around the 
globe but it is still a cause for concern as it contributes to the bulk of patients in 
developing countries. The West and European countries come up with emerging data 
and guidelines in management of early cervical cancers with advances in prevention 
and vaccination schedules as the bulk of their patients present in the early stages and 
only a few present in the locally advanced stage. Hence there is no necessity to 
improve the outcomes in this category of patients. This is not the case in our part of 
the world where majority of cases present in the locally advanced stage.  
 The outcome of early stage cervical is on the rise while the outcome of locally 
advanced FIGO Stage III.B disease has been static over the past decade with a 
modest 5 year survival of 45-50%. Thus, it is up to the developing countries like ours 
to come up with treatment strategies and guidelines to improve the outcome in this 
group of patients. 
 Radiotherapy has been a backbone in the management of cervical cancer since 
the early 1900s prior to which radical surgery and supportive management was the 
standard of care. Radiotherapy has revolutionized the management of cancer patients 
especially cervical cancer where Radiotherapy plays a role both in early and locally 
advanced disease status.  
 Several treatment strategies have been explored in the past to improve the 
outcome of locally advanced cervical cancer. This discussion will explore the 
treatment strategies that have been explored in the past and elaborate on the present 
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day strategy to improve local control. 
 The standard of care in managing locally advanced cervical cancer is 
Concurrent chemoradiation with weekly Cisplatin followed by intracavitary 
brachytherapy. This is based on the anouncement by NCI taking into account the 5 
randomized studies. Various radiosensitizers have been investigated in the past from 
hydroxyureas to the present day Cisplatin. Hyperbaric oxygen therapy was 
extensively investigated prior to the advent of Chemotherapy in cervical cancer, 
which showed good local control rates in locally advanced stages, but the 
inconvenience in delivering hyperbaric oxygen and its toxicity profile have made it 
unpopular. Research into more convenient methods of delivering hyperbaric oxygen 
with randomized trials along side chemotherapy and computer based dose 
modification to account for increased sensitivity of normal tissue and tumour may be 
required to establish its role in locally advanced disease. 
 Mitomycin C was found to be more beneficial in the more advanced stages as 
opposed to Cisplatin, whose benefit seems to decline with increasing stage.  
 Hyperthermia has also shown promising results in locally advanced disease 
where it can be used as an alternative for patients who are not fit for chemotherapy 
but it needs to be more convenient with improvement in controllability and precision 
in treatment delivery rather than the present day emperical approach. 
 The role of brachytherapy in cervical cancer is unquestionable but execution of 
intracavitary brachytherapy in locally advanced III.B disease especially with residual 
parametrial invasion and narrow vagina may be challenging. Such cases may benefit 
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from interstitial brachytherapy. Not many institutes practice Interstitial brachytherapy 
due to the equipment and the expertise required in application and planning. Studies 
have shown that the outcome of Intracavitary and Interstitial brachytherapy are 
comparable in FIGO Stage III.B and IV.A with selection bias favoring intracavitary 
brachytherapy. There is no randomized trial comparing intracavitary and interstitial 
brachytherapy. Randomized trials need to substantiate the benefit of interstitial 
brachytherapy in advanced FIGO Stage III.B cervical cancer not amenable to 
intracavitary brachytherapy. 
 The pattern of failure in locally advanced FIGO Stage III.B cervical cancer is 
predominantly due to local failure. Various dose escalation strategies have been under 
investigation. Dose escalation may also cause normal tissue toxicity. Grade III 
toxicities with conventional fractionated radiotherapy has been seen in about 23% of 
patients. Thus, dose escalation needs to be carried out by reducing the normal tissue 
toxicity or reducing the dose to organs at risk. 
 IMRT has revolutionized treatment planing with a better therapeutic ratio even 
in pelvic tumours. In view of the close proximity of organs at risk like rectum, small 
bowel and bladder to the target volume, multiple beams are required to ensure 
adequate PTV coverage while sparing organs at risk. 
 There have been many studies that have used IMRT-SIB in managing cervical 
cancer. It is beyond doubt that IMRT and IMAT – SIB provide a superior therapeutic 
ratio and dose distribution while sparing normal tissues adequately.  
 This article aims to assess the feasibility of concomitant boost using forward 
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planned conformal therapy in locally advanced cervical cancer. The rationale behind 
this treatment is to exploit the benefits of SIB-IMRT by escalating the dose to the 
gross tumour, optimizing the dose to the elective pelvic field and sparing organs at 
risk in a lesser treatment time compared to conventional fractionation. 
 In our study, 1.9 Gy per day for a total of 26 days (TD 49.4 Gy) was delivered 
to the PTV1 which included the whole pelvis apart from the boost volume(primary 
GTV) and 2.1 Gy per day for 26 days was delivered concomitantly to PTV2 which is 
the primary GTV (boost volume). 
 In conventional fractionation 50.4 Gy is delivered in 28 days at 1.8 Gy per day. 
This produces a homogeneous distribution which delivers higher dose to the elective 
volume and comparatively lower dose to the primary GTV. 
 The B.E.D received by the elective volume in conventional fractionated 
radiotherapy and concomitant boost are 59.4Gy and 58.7 Gy respectively. The B.E.D 
received by the primary tumour (boost volume) in conventional fractionation and 
concomitant boost are 64.4 Gy (with parametrial RT) and 66.06 Gy respectively. 
 The overall treatment time in conventional fractionation in about 6-7 weeks of 
external beam radiotherapy, followed by weekly intracavitary brachytherapy. 
Treatment planning was done with forward planning conformal therapy using field in 
field technique. 
 While none of the patients developed radiation induced acute Grade III 
morbidity, 3 patients developed chemotherapy induced Grade III morbidity requiring 
treatment breaks. 
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 11 patients (37.9%) had treatment breaks of more than 10 days of whom 9 
patients received chemotherapy but none of the prolonged breaks were related to 
treatment. The most common cause was due to the natural calamity that Chennai 
witnessed. 
 Between November 9th and December 6th Chennai was affected by rain and 
witnessed the worst floods in over a century which cost over 500 lives in Tamil nadu 
damaging property worth up to rupees 100,000 crores. While most of the schools, 
colleges, offices and hospitals remained closed during this period, our institute stood 
tall to function on all days with radiotherapy treatment machines not being turned on 
for only 3 days. Unfortunately, the patients who had treatment breaks had them 
because they were stranded in their native place with no source of transport into the 
city.  
 At presentation 10 patients complained of severe lower abdominal pain or 
lower backache with a pain score of 5 or more. After completion of treatment only 1 
patient persisted to have a pain score of 5 while none of the patients had bleeding / 
white discharge after completion of treatment. 
 18 patients did not develop radiation induced morbidity and tolerated treatment 
extremely well, while 12 patients developed radiation induce morbidity but none of 
them had Grade III toxicity. The rates of Proctitis, diarrhea and skin reaction were 
acceptable (17.2%, 10.3% and 6.89% respectively).  
 27.7% patients tolerated chemotherapy well without any acute morbidity. 
Grade III toxicity was seen in 3 patients (2 Neutropenia and 1 Hyponatremia) 
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requiring treatment breaks. The chemotherapy tolerability and the rate to GI 
morbidity were acceptable. 
 8 patients had local recurrence of whom 1 patient progressed to develop para-
aortic nodes and another patient had progressed in the Left Supraclavicular region. 
The patients who had local recurrence had poor prognostic factors at presentation. 3 
patients had histologies other than Squamous cell carcinoma and 3 patients had pelvic 
lymph nodes. 5 patients also had hydroureteronephrosis at presentation while 3 
patients could not undergo intracavitary brachytherapy in view of large necrotic 
disease.  
 Locally advanced cervical cancer continues to be a burden in developing 
countries. FIGO Stage III.B cervical cancer includes a wide spectrum of 
characteristics which cannot be managed with the same approach. Individualized 
treatment approach that is tailor-made for particular characteristics and identification 
of those high risk characteristics is the need of the hour. Categorizing patients and 
identifying strategies that may be suitable for them is essential. With the available 
information it is safe to say that Brachytherapy improves local control which 
translates to survival but local control strategies like dose escalation are required to 
achieve parameters to eventually execute brachytherapy. Dose escalation with 
concomitant boost is feasible with acceptable acute toxicity but long term follow up 
and randomized trials are required to validate the local control. In cases where the 
response to external beam radiation is inadequate, Image guided and interstitial 
brachytherapy should be made available. Chemotherapy with Cisplatin is the standard 
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of care but benefit of cisplatin reduces with increasing stage and the percentage of 
patients with Stage III.B disease receiving Cisplatin may also be less due to the renal 
dysfunction that may be caused due to the disease. Hence other radiosensitizers and 
advances in Hyperthermia and hyperbaric oxygen therapy may be beneficial in this 
sub group of patients but further studies are required to substantiate this.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
75 
 
CONCLUSION 
 Concomitant boost using conformal technique is feasible in locally advanced 
cervical cancer with acceptable toxicity profile. The patients enrolled in this study 
were locally advanced Stage III.B with bulky disease. Although the local response 
rates with concomitant boost appears to be satisfactory, long term follow up and 
further randomized studies with standard chemoradiation is necessary before coming 
to any conclusion. 
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